Ribonucleic Acid News and Research

RSS

Impact of a third BNT162b2 dose on SARS-CoV-2 Omicron variant

In a new study, researchers assessed the extent and duration of the neutralization of SARS-CoV-2 Omicron variant of concern after the administration of two and three doses of the BNT162b2 mRNA vaccine.

25 Jan 2022

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

A new preprint available on medRxiv* demonstrates the marked improvement in the immune response when the mRNA vaccine BNT162b2, from Pfizer/BioNTech, is used for the third dose after a primary two-dose series of an inactivated whole virus vaccine.

25 Jan 2022

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

The current paper compares the effectiveness of two vs. three doses of these vaccines against Omicron compared to Delta.

25 Jan 2022

Attenuated tissue immune responses against SARS-CoV-2 in obese and non-obese patients

In a new study, researchers evaluated the single-cell transcriptomes from bronchiolar lavage in three adult cohorts comprising of obese and non-obese SARS-CoV-2 patients.

24 Jan 2022

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United States Food and Drug Administration (FDA) for their in vitro potency against several SARS-CoV-2 variants, including the currently dominant Omicron train.

23 Jan 2022

Novel SARS-CoV-2 mutations reported in chronic HIV patients

A new study describes the emergence of new SARS-CoV-2 variants in three immunocompromised patients.

23 Jan 2022

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Researchers describe the state of adaptive immunity following vaccination with the Pfizer-BioNTech BNT162b2 COVID-19 vaccine.

23 Jan 2022

Paxlovid provides a glimpse into the future against SARS-CoV-2

A recent study reveals that nirmatrelvir is potent and effective against the SARS-CoV-2 Omicron variant.

23 Jan 2022

Is COVID-19 mRNA vaccination in children associated with subsequent multisystemic hyper-inflammatory syndrome?

Researchers assessed the possibility of COVID-19 mRNA vaccines causing multisystem inflammatory syndrome in children aged 12 to 17 years in France.

20 Jan 2022

Antibodies to SARS-CoV-2 and infection risk in healthcare workers following mRNA vaccination

A new study aimed to understand the risk of COVID-19 infection given certain serological parameters, in a group of vaccinated healthcare workers with high rates of exposure to the virus, followed up at 9 months from vaccination.

20 Jan 2022

Recombinant bat coronavirus reported in wide-ranging Cambodian bat

A new study reports on the detection of recombinant coronaviruses in several bat species in Cambodia and of a related species in China.

20 Jan 2022

Exploring the interactions between multiple respiratory viruses

A recent report explores the dynamics of viral interference between various respiratory viruses in light of the ongoing COVID-19 pandemic.

19 Jan 2022

Emerging nanomaterials-based biosensor for detecting SARS-CoV-2

A new study aimed to highlight the different smart and emerging nanomaterials used to detect SARS-CoV-2.

19 Jan 2022

Chinese scientists reveal key role of lysosome cell death regulator in lung tumor survival

Chinese scientists recently reported the key role of histone acetylation-regulated long noncoding RNA termed as lysosome cell death regulator (LCDR) in tumor survival, providing a potential diagnostic and therapeutic target for lung cancer.

18 Jan 2022

Applications of bioconjugated nanomaterials in SARS-CoV-2 diagnostics

In this study, the researchers not only elucidate the recent bioconjugated nanomaterials for targeted diagnosis of SARS-CoV-2, but they also provide the rationale behind these developments by discussing the mechanisms and approaches.

18 Jan 2022

Evidence that monoclonal antibodies can reduce COVID-19 (Delta) mortality

Researchers prevent evidence on the efficacy of neutralizing monoclonal antibodies in treating COVID-19.

17 Jan 2022

Sniffer dogs detect long COVID after 1.5 years

Researchers used sniffer dogs to test the presence of SARS-CoV-2 infection in axillary sweat samples of long COVID-19 patients.

17 Jan 2022

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

A new paper discusses the appearance of quasi-species in a single host with prolonged infection, with different rates of infectivity and sensitivity to neutralization by antibodies elicited by the Pfizer vaccine or those present in convalescent plasma.

17 Jan 2022

Nine-month survey of COVID-19 vaccine effectiveness in North Carolina

A new paper reports increased breakthrough infections with SARS-CoV-2, the agent behind the ongoing COVID-19 pandemic.

17 Jan 2022

Study investigates whether immune responses to BNT162b2 vaccine differ in subjects with and without prior SARS-CoV-2 infection

A new paper published in the journal JCI Insight reports on the differential levels of immunity achieved in those with and without a history of prior infection with the virus following one and two doses of the earliest vaccines to be approved for emergency use.

17 Jan 2022

Ribonucleic Acid News and Research

Impact of a third BNT162b2 dose on SARS-CoV-2 Omicron variant

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

Attenuated tissue immune responses against SARS-CoV-2 in obese and non-obese patients

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

Novel SARS-CoV-2 mutations reported in chronic HIV patients

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Paxlovid provides a glimpse into the future against SARS-CoV-2

Is COVID-19 mRNA vaccination in children associated with subsequent multisystemic hyper-inflammatory syndrome?

Antibodies to SARS-CoV-2 and infection risk in healthcare workers following mRNA vaccination

Recombinant bat coronavirus reported in wide-ranging Cambodian bat

Exploring the interactions between multiple respiratory viruses

Emerging nanomaterials-based biosensor for detecting SARS-CoV-2

Chinese scientists reveal key role of lysosome cell death regulator in lung tumor survival

Applications of bioconjugated nanomaterials in SARS-CoV-2 diagnostics

Evidence that monoclonal antibodies can reduce COVID-19 (Delta) mortality

Sniffer dogs detect long COVID after 1.5 years

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

Nine-month survey of COVID-19 vaccine effectiveness in North Carolina

Study investigates whether immune responses to BNT162b2 vaccine differ in subjects with and without prior SARS-CoV-2 infection

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News